Brixton Biosciences Receives 2M NIH HEAL Initiative Grant to Drive Drug-Free Pain Relief Innovations

LSTA Stock  USD 2.82  0.02  0.70%   
About 61% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Brixton Biosciences, a clinical-stage life sciences company, today announced it has been awarded first-year funding of a 2 million grant from the National Institutes of Health through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. The grant will support Brixtons ongoing development of Neural Ice, an injectable, drug-free pain management technology designed to provide long-lasting relief from chronic and post-operative pain. This funding is

Read at finance.yahoo.com
Yahoo News
  

Lisata Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lisata Therapeutics Fundamental Analysis

We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Lisata Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Lisata Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.

Peers

Lisata Therapeutics Related Equities

PULMPulmatrix   16.69   
0%
92.0%
CADLCandel Therapeutics   7.14   
0%
39.0%
GLUEMonte Rosa   5.93   
0%
32.0%
LIXTLixte Biotechnology   5.34   
0%
29.0%
RZLTRezolute   4.18   
0%
23.0%
IMNNImunon   3.61   
0%
19.0%
MBRXMoleculin Biotech   2.67   
0%
14.0%
TPSTTempest Therapeutics   2.12   
0%
11.0%
XOMAOXOMA   0.36   
0%
1.0%
ANTXAN2 Therapeutics   1.44   
7.0%
0%
BPTHBio Path   3.74   
20.0%
0%
KAKineta   7.69   
42.0%
0%
PTIXProtagenic Therapeutics   18.08   
100.0%
0%

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories